The authors state that errors occurred during formatting of Fig 2B and Supplementary Fig 3C during the submission process of the original manuscript. The histogram of Fig 2B was mistakenly duplicated in Supplementary Fig S3C. The corrected histogram of Supplementary Fig S3C is shown below. In addition, Fig 2B contains two labeling errors of P‐values, originating from mistakes in the labeling during the graphical assembly of the figure: The P‐value for OSBPL3‐shRNA vs. scrambled shRNA should read instead of , and the P‐value for GJB3‐shRNA vs. scrambled shRNA should read instead of . The corrected Fig 2B is shown below. For the experiments shown in Fig 2B and Supplementary Fig S3C, a total number of 74–174 cells was analyzed in 3–14 vision fields per cell line.
Further, γH2AX staining of IMR90 cells mentioned in the results section (page 1373, last sentence “… telomerase‐negative BJ and IMR90 fibroblasts exhibited a strong accumulation of DNA damage (staining positive for both γH2AX and 53BP1) at early passage after shRNA transduction (Fig 2A, C and D, Supplementary Fig S3A and B)…” was not depicted in the paper, and the 53BP1 staining was performed only on the BJ cells. To correct for this mistake, the text and data presentation of the result section on the description of DNA damage foci (page 1373, last sentence, and page 1374, first paragraph) is specified as follows: “The experiments on IMR90 cells were conducted only for γH2AX staining. These results are now provided in Supplementary Fig S8”.
The description and presentation of Western blot results in Fig 1D (page 1372, first paragraph on the right column) is corrected as follows: The depicted analyses of p‐p53, p‐p38, and GAPDH in Fig 1D (see also the corresponding Source Data file in the original article) were all analyzed from the same blot. A repeat of the p‐p53 Western blot was run on a separate gel using the same protein lysates and loading buffer (see Source data for Figure 1D below).
The Western blot for p21 in Fig 1D and the corresponding beta‐actin control were run in parallel with the same protein lysates and the same loading on 2 separate gels; the gel probed for beta‐actin was not shown in the original source data file of Fig 1D. The gel was also used to repeat the analysis of p‐p38 expression (see Source data for Figure 1D below). Results of p21 induction were confirmed by immunofluorescence analysis (see Fig 1E and Supplementary Fig S2H–K of the original manuscript).
The corrections do not affect the original conclusions presented. The authors apologize for the mistakes and any inconvenience they might have caused.
The structure of cyclocreatine is fairly flat (planar), which aids in passive diffusion across membranes. It has been used with success in an animal study, where mice suffered from a SLC6A8 (creatine transporter at the blood brain barrier) deficiency, which is not responsive to standard creatine supplementation.  This study failed to report increases in creatine stores in the brain, but noted a reduction of mental retardation associated with increased cyclocreatine and phosphorylated cyclocreatine storages.  As demonstrated by this animal study and previous ones, cyclocreatine is bioactive after oral ingestion   and may merely be a creatine mimetic, able to phosphorylate ADP via the creatine kinase system. 
The main symptoms of vitamin D overdose which are those of hypercalcemia including anorexia , nausea, and vomiting. These may be followed by polyuria , polydipsia , weakness, insomnia, nervousness, pruritus and ultimately renal failure . Furthermore, proteinuria , urinary casts , azotemia , and metastatic calcification (especially in the kidneys) may develop.  Other symptoms of vitamin D toxicity include mental retardation in young children, abnormal bone growth and formation, diarrhea, irritability, weight loss, and severe depression.